Edwards Lifesciences (EW) Tops Q2 EPS by 9c; Raises Outlook

Edwards Lifesciences (NYSE: EW) reported Q2 EPS of $0.64, $0.09 better than the analyst estimate of $0.55. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.28 billion.

GUIDANCE:

Edwards Lifesciences sees FY2021 EPS of $2.07-$2.27, versus the consensus of $2.21. Edwards Lifesciences sees FY2021 revenue of $5.2-5.4 billion, versus the consensus of $5.17 billion.

For earnings history and earnings-related data on Edwards Lifesciences (EW) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Amneal gets FDA approval for lanreotide injection, launches immediately
• Is the S&P 500 in an "earnings bubble"? Goldman weighs in